久操视频网站,又大又粗又黄又刺激的免费视频,亚洲三级电影在线播放,国产亚洲视频在线观看二区

中文
中文

以患者需求為核心,驅(qū)動(dòng)細(xì)胞免疫治療創(chuàng)新,實(shí)現(xiàn)癌癥可控化并最終治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.
 

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
  • 0


On the cover: 
The transdifferentiation paths of erythroid precursor cells (EPCs) under the influence of tumor is delineated from Palantir algorithm‐based single-cell transcriptomic trajectory analysis (Long et al., 674–693), and embedded into artwork inspired by Wassily Kandinsky's “Composition 8.” As acquired “organs,” tumors exert a self-beneficial influence on the immune system by hijacking of erythropoiesis for myelopoiesis. Besides exacerbating anemia, CD45+ EPCs transdifferentiation generates myeloid cells that robustly curtail anti‐tumor immunity. Clinically, the abundance of these converted cells predicts immune tolerance in many human tumor types and resistance to immune checkpoint inhibitor treatment. Design and painting by Yijie Hou. Conceptual visualization by Qi-Jing Li and Bo Zhu.

https://www.cell.com/cancer-cell/current#closeFullCover

 

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號(hào)

粵ICP備20056630號(hào) Powered by vancheer

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號(hào)

粵ICP備20056630號(hào) Powered by vancheer